Moderna's mRNA influenza vaccine has secured FDA approval following significant regulatory developments. The agency initially declined to review the application but reversed its decision in response to considerable public pressure and advocacy. This milestone represents an important expansion of mRNA technology beyond COVID-19 vaccines into seasonal flu prevention. The approval demonstrates the growing confidence in mRNA platform effectiveness and opens new possibilities for combating influenza with advanced immunological approaches.

Summary auto-generated by AI from the original publisher's content. Editorial standards.